Zach Rozenbaum1, Sydney Benchetrit2,3, Saar Minha2,4, Yoram Neuman2,5, Meital Shlezinger6, Ilan Goldenberg2,6, Morris Mosseri2,5, David Pereg2,5. 1. Department of Internal Medicine D, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel. 4. Cardiology Department, Assaf HaRofeh Medical Center, Tzrifin, Israel. 5. Department of Cardiology, Meir Medical Center, Kfar Saba, Israel. 6. Department of Cardiology, Sheba Medical Center, Tel HaShomer, Israel.
Abstract
BACKGROUND: Chronic kidney disease is a frequent comorbidity among patients with acute coronary syndrome (ACS). We aimed to evaluate treatment characteristics in ACS patients according to their renal function and to assess the effect of differences in therapy on clinical outcomes. METHODS: Included were patients with ACS enrolled in the biennial Acute Coronary Syndrome Israeli Surveys (ACSIS) during 2000-2013. Excluded were patients with cardiogenic shock at presentation. The estimated glomerular filtration rate (eGFR) was calculated using the simplified Modification of Diet in Renal Disease (MDRD) formula. The distribution of the eGFRs was divided into 4 categories (<45, 45-59.9, 60-74.9, and ≥75 mL/min/1.73 m2). The primary endpoint was all-cause mortality at 1 year. RESULTS: A total of 13,194 patients with ACS were included. Patients with a reduced eGFR were less likely to be admitted to a coronary care unit and had lower rates of coronary angiograms and subsequent percutaneous coronary interventions. Furthermore, as the eGFR was lower, the patients were less frequently treated with aspirin, clopidogrel, β-blockers, and ACE inhibitors/angiotensin receptor blockers. We demonstrated an inverse association between renal function and 1-year mortality, with the highest mortality rates observed in the group with the lowest eGFR (HR = 3.8, 95% CI 2.9-4.9, p < 0.0001). Differences in mortality remained significant following a multivariate analysis for all the baseline characteristics as well as for invasive and medical treatment (HR = 2.7, 95% CI 1.9-3.7, p < 0.0001). CONCLUSIONS: ACS patients with chronic kidney disease represent a high-risk group with an increased mortality risk. Despite this high risk, these patients are less frequently selected for an invasive treatment strategy and are less commonly treated with guideline-based medications. However, reduced renal function was associated with higher mortality regardless of the variations in therapy.
BACKGROUND:Chronic kidney disease is a frequent comorbidity among patients with acute coronary syndrome (ACS). We aimed to evaluate treatment characteristics in ACS patients according to their renal function and to assess the effect of differences in therapy on clinical outcomes. METHODS: Included were patients with ACS enrolled in the biennial Acute Coronary Syndrome Israeli Surveys (ACSIS) during 2000-2013. Excluded were patients with cardiogenic shock at presentation. The estimated glomerular filtration rate (eGFR) was calculated using the simplified Modification of Diet in Renal Disease (MDRD) formula. The distribution of the eGFRs was divided into 4 categories (<45, 45-59.9, 60-74.9, and ≥75 mL/min/1.73 m2). The primary endpoint was all-cause mortality at 1 year. RESULTS: A total of 13,194 patients with ACS were included. Patients with a reduced eGFR were less likely to be admitted to a coronary care unit and had lower rates of coronary angiograms and subsequent percutaneous coronary interventions. Furthermore, as the eGFR was lower, the patients were less frequently treated with aspirin, clopidogrel, β-blockers, and ACE inhibitors/angiotensin receptor blockers. We demonstrated an inverse association between renal function and 1-year mortality, with the highest mortality rates observed in the group with the lowest eGFR (HR = 3.8, 95% CI 2.9-4.9, p < 0.0001). Differences in mortality remained significant following a multivariate analysis for all the baseline characteristics as well as for invasive and medical treatment (HR = 2.7, 95% CI 1.9-3.7, p < 0.0001). CONCLUSIONS: ACS patients with chronic kidney disease represent a high-risk group with an increased mortality risk. Despite this high risk, these patients are less frequently selected for an invasive treatment strategy and are less commonly treated with guideline-based medications. However, reduced renal function was associated with higher mortality regardless of the variations in therapy.
Entities:
Keywords:
Acute coronary syndrome; Outcome; Renal function
Authors: Tammy M Keough-Ryan; Bryce A Kiberd; Christine S Dipchand; Jafna L Cox; Caren L Rose; Kara J Thompson; Catherine M Clase Journal: Am J Kidney Dis Date: 2005-11 Impact factor: 8.860
Authors: Roxana Mehran; Stuart J Pocock; Eugenia Nikolsky; Tim Clayton; George D Dangas; Ajay J Kirtane; Helen Parise; Martin Fahy; Steven V Manoukian; Frederick Feit; Magnus E Ohman; Bernard Witzenbichler; Giulio Guagliumi; Alexandra J Lansky; Gregg W Stone Journal: J Am Coll Cardiol Date: 2010-06-08 Impact factor: 24.094
Authors: Steven V Manoukian; Frederick Feit; Roxana Mehran; Michele D Voeltz; Ramin Ebrahimi; Martial Hamon; George D Dangas; A Michael Lincoff; Harvey D White; Jeffrey W Moses; Spencer B King; E Magnus Ohman; Gregg W Stone Journal: J Am Coll Cardiol Date: 2007-03-09 Impact factor: 24.094
Authors: Caroline Medi; Gilles Montalescot; Andrzej Budaj; Keith A A Fox; José López-Sendón; Gordon FitzGerald; David B Brieger Journal: JACC Cardiovasc Interv Date: 2009-01 Impact factor: 11.195
Authors: Yong Huo; Frans Van de Werf; Yaling Han; Xavier Rossello; Stuart J Pocock; Chee Tang Chin; Stephen W-L Lee; Yi Li; Jie Jiang; Ana Maria Vega; Jesús Medina; Héctor Bueno Journal: Am J Cardiovasc Drugs Date: 2021-02-04 Impact factor: 3.571
Authors: José Miguel Rivera-Caravaca; Juan Miguel Ruiz-Nodar; Antonio Tello-Montoliu; María Asunción Esteve-Pastor; Miriam Quintana-Giner; Andrea Véliz-Martínez; Esteban Orenes-Piñero; Ana Isabel Romero-Aniorte; Nuria Vicente-Ibarra; Vicente Pernias-Escrig; Luna Carrillo-Alemán; Elena Candela-Sánchez; Ignacio Hortelano; Beatriz Villamía; Miriam Sandín-Rollán; Laura Nuñez-Martínez; Mariano Valdés; Francisco Marín Journal: J Am Heart Assoc Date: 2018-04-21 Impact factor: 5.501
Authors: Patrick Bidulka; Jemima Scott; David Adlam; Dorothea Nitsch; Dominic M Taylor; Udaya Udayaraj; Fergus Caskey; Lucy Teece; Michael Sweeting; John Deanfield; Mark de Belder; Spiros Denaxas; Clive Weston Journal: BMJ Open Date: 2022-03-28 Impact factor: 2.692